Alkermes Presents Data at NEI Fall Congress

The company will share research on its psychiatry and sleep portfolios at the November 5 to 8 meeting in Colorado Springs.

Updated on Nov. 7, 2026 in Substance Abuse

Close view of a water glass and carafe on a dark wooden lectern, with empty rows of seats receding into soft shadow in a conference hall. — Alkermes will present research on its psychiatry and sleep-disorder medications, including Lybalvi, Aristada, Lumryz, and alixorexton, at the NEI Fall Congress in Colorado Springs, November 5 to 8. AI Illustration. Upload story photo >

Alkermes plc will present research data from its psychiatry and sleep portfolios at the NEI Fall Congress, held November 5 to 8, 2026, in Colorado Springs, Colorado. Presentations cover Lybalvi, Aristada, Lumryz extended-release oral suspension, and the investigational compound alixorexton.

Why it matters

The presentations extend Alkermes' published research across schizophrenia, bipolar I disorder, and sleep disorders, including data on acute care events in patients with comorbid alcohol use disorder. The company's presentations follow a series of research releases it made at Psych Congress, ISBD, and AMCP Nexus this fall.

The presented evidence consists of company-announced conference presentations, including a 12-month before-and-after analysis of acute care events after Lybalvi initiation in patients with schizophrenia or bipolar I disorder and comorbid alcohol use disorder. The findings themselves have not been released, and the source does not report results.

The players

Alkermes plc

Alkermes plc is an Irish biopharmaceutical company that develops treatments for central nervous system disorders, including schizophrenia, bipolar disorder, and sleep disorders.

The details

Alkermes will present data on Lybalvi, Aristada, Lumryz extended-release oral suspension, and alixorexton, an investigational oral OX2R agonist in development for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. One accepted presentation assesses acute care events in patients with schizophrenia or bipolar I disorder and comorbid alcohol use disorder after initiating Lybalvi, while the ASPIRE study, a real-world patient-centred online survey, explores links between depression and disease burden in adults with narcolepsy and idiopathic hypersomnia.

September 15-19, 2026: Alkermes presented research at Psych Congress in New Orleans.
September 28-30, 2026: Alkermes presented research at the ISBD annual conference in Vancouver.
October 26-29, 2026: Alkermes presented research at AMCP Nexus in San Diego.
November 5-8, 2026: NEI Fall Congress in Colorado Springs, Colorado, where Alkermes presents data.

Health Landscape

The presentations extend post-approval research on Lybalvi, the once-daily olanzapine-samidorphan tablet approved in the United States for schizophrenia and bipolar I disorder. They add to a growing body of real-world evidence on antipsychotic treatment outcomes in patients with co-occurring alcohol use disorder.

For patients with schizophrenia or bipolar I disorder who also have alcohol use disorder, the research may inform discussions with clinicians about treatment options and monitoring for acute care needs. Patients with narcolepsy or idiopathic hypersomnia may find the depression and disease-burden findings useful when discussing their condition with a doctor.

The takeaway

The research highlights how clinicians and researchers are tracking real-world outcomes for antipsychotic treatments, particularly in patients with co-occurring alcohol use disorder. Readers managing these conditions should discuss any questions about treatment outcomes with their healthcare provider.